ECOG- Frequently Asked Questions about the Multiple Myeloma Study (E1A00)

ECOG: The Eastern Cooperative Oncology Group

ECOG
Introduction to ECOG

Clinical Trials
Guide For Cancer Patients
What is a clinical trial?
Why participate?
Does insurance cover costs?
What if I change my mind?
How can I join a clinical trial?
ECOG's active protocols
Patient Information
Selenium E5597
Colorectal E4203
Colon E5202
Melanoma E2603
Prostate CHAARTED E3805
Rectal E5204
Cancer in Siblings E1Y97
Non-Hodgkins Lymphoma E4402
Breast Cancer PACCT1: TAILORx
Informational Videos
Trial Summary Results

Trial Monitoring
ECOG Data Monitoring Committee

ECOG Institutions
Institutions by state
Alphabetical listing
Joining ECOG

Publications
Publications bibliography

Announcements
NCI Press Release: Bevacizumab...
Job Openings
Future ECOG Meeting Dates
Researcher Advocate Partners
Investigator Awards
NCI-VA Initiative
Hurricane Katrina

Scales and Criteria
ECOG Performance Status
Common Toxicity Criteria

Cancer Information
Breast Cancer Video
Colon Cancer Video
Cancer Survivor Publications
Releasing Results Guidelines

Other Cancer Sites
ECOG Main Institutions' Sites
Other Cooperative Groups
Advocates/Support Groups

ECOG HOME PAGE

ECOG MEMBERS
INFORMATION
(password required)

GLOSSARY

SEARCH

CONTACT INFORMATION

DISCLAIMER

ECOG- Frequently Asked Questions about the Multiple Myeloma Study (E1A00)

Follow the links below to view an announcement and a handout answering frequently asked questions about the ECOG Multiple Myeloma Study (E1A00). This is a "randomized Phase III trial of Thalidomide (NSC#66847) plus Dexamethasone versus Dexamethasone in newly diagnosed Multiple Myeloma".

Multiple Myeloma Clinical Trial Announcement

Frequently Asked Questions about the Multiple Myeloma Study

The document is in Adobe Acrobat format. If you do not already have Adobe Acrobat Reader running on your computer you can download this software free of charge from the Adobe web site.

Next topic

How to contact ECOG